Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression have?
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression has 339 citations in the OpenAlex counts ScholarIQ stores.
When was Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression published?
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression has 2019 year in the ScholarIQ index.
What is the open-access status of Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression?
Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression has hybrid oa status in the ScholarIQ index.
What is the DOI of Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression?
The DOI for Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression is on the source record.
What is the PMID of Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression?
The PMID for Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression is on the source record.
What is the OpenAlex record for Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression?
The OpenAlex for Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression is on the source record.